Trending Topic

3D illustration of human brain on black background
23 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Joseph Samaha, Jim Dagher, Shayan Abdollah Zadegan

Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of CAG repeats results in the production of a mutant huntingtin protein with an abnormally long polyglutamine […]

Cognitive and Behavioural Predictors of Alzheimer’s Disease Progression

John M Starr, Tom C Russ, Sarah McGrory
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: May 15th 2012 European Neurological Review, 2012;7(2):103-6 DOI: http://doi.org/10.17925/ENR.2012.07.02.103
Select a Section…
1

Abstract

Overview

Alzheimer’s disease (AD) can be thought of as divided into pre- and post-diagnostic phases. There is evidence that cognitive and behavioural traits influence the risk of AD diagnosis. Following diagnosis, it may be difficult to tangle the causal direction between cognitive and behavioural measures as predictors or manifestations of AD progress, though people with higher lifetime cognitive trait scores appear to be protected somewhat against worsening cognitive scores and behavioural changes. The pre-diagnostic phase can be considered as a state where AD neuropathology is progressing without manifestations of this and a prodromal phase where, typically, episodic memory is impaired. Far fewer data exist that inform about the effects of cognitive or behavioural predictors during this phase, though those from large brain tissue bank collaborations indicate that education, a correlate of cognitive function, does not influence the extent of neuropathology.

Keywords

Alzheimer’s disease, dementia, disease progression, Down syndrome, cognition, neuropsychiatric symptoms, activities of daily living, depression, item response theory

2

Article

Alzheimer’s disease (AD) is the commonest cause of dementia. It is characterised by the presence of senile amyloid plaques and neurofibrillary tangles and clinical characteristics consistent with gradual deterioration in memory function of at least six months duration together with other neuropsychological deficits, most typically aphasia, agnosia, apraxia and disturbance in executive function. Although, strictly speaking, AD cannot be diagnosed in the absence of clinical features, it is generally accepted that there is a preclinical phase that can be present for several years during which the underlying pathological features are progressing. Sometimes a further prodromal phase is defined, manifested as amnestic mild cognitive impairment (aMCI)1. aMCI is a state where memory function is impaired at least 1.5 standard deviations below the mean, but where other cognitive domains remain relatively unaffected and where there is none or only minimal impairment of social function and activities of daily living (ADL). Once a person has entered the clinical phase of AD, non-memory cognitive domains are progressively involved together with deterioration in ADL. Figure 1 demonstrates this schema of AD progression.

A Clinical Dementia Rating (CDR) scale2 has been devised to reflect this progression in both cognition and ADL. The CDR rating can take the value of zero for absence of dementia, 0.5 very mild, 1.0 mild, 2.0 moderate and 3.0 severe dementia.

In addition, progression to clinical AD may also be accompanied by behavioural changes. Such changes may occur at any phase and insome types of AD, such as that seen in adults with Down syndrome (DS), typically occurs at an early stage and may be an initial symptom.3 Moreover, some psychological or behavioural symptoms may pre-date clinical AD by several years and thus be considered as predictors of progression.

In this review, we will consider cognitive and behavioural predictors relevant to each stage of AD progression as represented in Figure 1.

To view the full article in PDF or eBook formats, please click on the icons above.

2

References

  1. Petersen RC, Mild cognitive impairment as a diagnostic
    entity, J Intern Med, 2004;256:183–94.

  2. Morris JC, The Clinical Dementia Rating (CDR): current
    version and scoring rules, Neurology, 1993;43:2412–4.

  3. Roizen NJ, Patterson D, Down’s syndrome, Lancet,
    2003;361:1281–9.

  4. Brayne C, Ince PG, Keage HAD, et al., Education, the brain
    and dementia: neuroprotection or compensation?, Brain,
    2010;133:2210–6.

  5. Cummings JL, Cognitive and behavioral heterogeneity in
    Alzheimer’s disease: seeking the neurobiological basis,
    Neurobiol Aging, 2000;21:845–61.

  6. Deary IJ, Whalley LJ, Lemmon H, et al., The stability of
    individual differences in mental ability from childhood
    to old age: Follow-up of the 1932 Scottish Mental
    Survey, Intelligence, 2000;28:49–55.

  7. Crawford JR, Deary IJ, Starr J, Whalley LJ, The NART as an
    index of prior intellectual functioning: a retrospective
    validity study covering a 66-year interval, Psychol Med,
    2001;31:451–8.

  8. Starr JM, Whalley LJ, Inch S, Shering PA, The quantification
    of the relative effects of age and NART‐predicted IQ
    on cognitive function in healthy old people,
    Int J Geriatr Psychiatry, 1992;7:153–7.

  9. Deary IJ, Starr JM, MacLennan W, Fluid intelligence, memory
    and blood pressure in cognitive aging, Pers Indiv Differ,
    1998;25:605–19.

  10. Whalley LJ, Sharma S, Fox HC, et al., Anticholinergic drugs in
    late life: adverse effects on cognition but not on progress to
    dementia, J Alzheimers Dis, 2012;30:253–61.

  11. Reid LM, MacLullich AMJ, Subjective memory
    complaints and cognitive impairment in older
    people, Dement Geriatr Cogn Dis, 2006;22:471–85.

  12. Braak H, Braak E, Frequency of stages of Alzheimer-related
    lesions in different age categories, Neurobiol Aging,
    1997;18:351–7.

  13. Byers AL, Yaffe K, Depression and risk of developing
    dementia, Nat Rev Neurol, 2011;7:323–31.

  14. Barnes DE, Yaffe K, McCormick M, Schaefer C, et al., Midlife
    versus late-life depression and risk of dementia: Differential
    effects for vascular dementia and Alzheimer’s disease,
    Alzheimer Dement, 2010;6:S109.

  15. Gatz JL, Tyas SL, John PS, Montgomery P, Do depressive
    symptoms predict Alzheimer’s disease and dementia?,
    J Gerontol A Biol, 2005;60:744–7.

  16. Byers AL, Covinsky KE, Barnes DE, Yaffe K, Dysthymia and
    depression increase risk of dementia and mortality among
    older veterans, Am J Geriatr Psychiat, 2011 May 18 [Epub ahead
    of print].

  17. Russ TC, Hamer M, Stamatakis E, et al., Psychological
    distress as a risk factor for dementia death,
    Arch Intern Med, 2011;171:1858–9.

  18. Brown ES, Varghese FP, McEwen BS, Association of
    depression with medical illness: does cortisol play a role?,
    Biol Psychiatry, 2004;55:1–9.

  19. Alexopoulos GS, Meyers BS, Young RC, et al., ‘Vascular
    depression’ hypothesis, Arch Gen Psychiatr, 1997;54:915–22.

  20. Baldwin RC, Is vascular depression a distinct sub-type of
    depressive disorder? A review of causal evidence,
    Int J Geriatr Psychiatry, 2005;20:1–11.

  21. Whitmer RA, Sidney S, Selby J, et al., Midlife cardiovascular
    risk factors and risk of dementia in late life, Neurology,
    2005;64:277–81.

  22. Parra MA, Abrahams S, Logie RH, et al., Visual short-term
    memory binding deficits in familial Alzheimer’s disease,
    Brain, 2010;133:2702–13.

  23. Whalley L, Starr J, Athawes R, et al., Childhood mental ability
    and dementia, Neurology, 2000;55:1455–9.

  24. McGurn B, Deary IJ, Starr JM, Childhood cognitive ability and
    risk of late-onset Alzheimer and vascular dementia,
    Neurology, 2008;71:1051–6.

  25. Whalley LJ, Deary IJ, Appleton CL, Starr JM, Cognitive
    reserve and the neurobiology of cognitive aging,
    Ageing Res Rev, 2004;3:369–82.

  26. Deary IJ, Whiteman MC, Pattie A, et al., The APOE epsilon 4
    allele and cognitive change from age 11 to age 80, Nature,
    2002;418:932.

  27. Hamilton G, Harris SE, Davies G, et al., Alzheimer’s disease
    genes are associated with measures of cognitive ageing
    in the lothian birth cohorts of 1921 and 1936,
    Int J Alzheimers Dis, 2011 Jun 12 [Epub ahead of print].

  28. Teng E, Lu PH, Cummings JL, Neuropsychiatric symptoms
    are associated with progression from mild
    cognitive impairment to Alzheimer’s disease,
    Dement Geriatr Cogn Disord, 2007;24:253–9.

  29. Hsiung GYR, Alipour S, Jacova C, et al., Transition from
    cognitively impaired not demented to Alzheimer’s disease:
    an analysis of changes in functional abilities in a dementia
    clinic cohort, Dement Geriatr Cogn Disord, 2008;25:483–90.

  30. Amieva H, Le Goff M, Millet X, et al., Prodromal Alzheimer’s
    disease: successive emergence of the clinical symptoms,
    Ann Neurol, 2008;64:492–8.

  31. McGurn B, Starr J, Topfer J, et al., Pronunciation of irregular
    words is preserved in dementia, validating premorbid IQ
    estimation, Neurology, 2004;62:1184–6.

  32. Starr JM, Lonie J, The influence of pre-morbid IQ on
    Mini-Mental State Examination score at time of dementia
    presentation, Int J Geriatr Psychiatry, 2007;22:382–4.

  33. Starr J, Lonie J, Estimated pre-morbid IQ effects on cognitive
    and functional outcomes in Alzheimer disease: a
    longitudinal study in a treated cohort, BMC Psychiatry,
    2008;8:27.

  34. McHorney CA, Haley SM, Ware JE, Evaluation of the MOS
    SF-36 physical functioning scale (PF-40): II. Comparison of
    relative precision using Likert and Rasch scoring methods,
    J Clin Epidemiol, 1997;50:451–61.

  35. Morales LS, Flowers C, Gutierrez P, et al., Item and scale
    differential functioning of the Mini-Mental State Exam
    assessed using the differential item and test functioning
    (DFIT) framework, Med Care, 2006;44:S143.

  36. Schultz-Larsen K, Kreiner S, Lomholt RK, Mini-Mental Status
    Examination: mixed Rasch model item analysis derived
    two different cognitive dimensions of the MMSE,
    J Clin Epidemiol, 2007;60:268–79.

  37. Galasko D, An integrated approach to the management of
    Alzheimer’s disease: assessing cognition, function and
    behaviour, Eur J Neurol, 1998;5:S9–S17.

  38. Njegovan V, Man-Son-Hing M, Mitchell SL, Molnar FJ, The
    hierarchy of functional loss associated with cognitive
    decline in older persons, J Gerontol A Biol, 2001;56:M638–M43.

  39. Daltroy LH, Logigian M, Iversen MD, Lian MH, Does
    musculoskeletal function deteriorate in a predictable
    sequence in the elderly?, Arthritis Rheum, 1992;5:146–50.

  40. Kovar MG, Powell Lawton M, Functional disability: Activities
    and instrumental activities of daily living, Annual Review of
    Gerontology and Geriatrics, 1994;14:57–75.

  41. Norström T, Thorslund M, The structure of IADL and
    ADL measures: some findings from a Swedish study,
    Age Ageing, 1991;20:23–8.

  42. Ligtvoet R, van der Ark LA, te Marvelde JM, Sijtsma K,
    Investigating an invariant item ordering for polytomously
    scored items, Educ Psychol Meas, 2010;70:578–95.

  43. Fieo R, Watson R, Deary IJ, Starr JM, A revised activities of
    daily living/instrumental activities of daily living instrument
    increases interpretive power: theoretical application for
    functional tasks exercise, Gerontology, 2010;56:483–90.

  44. Fieo RA, Austin EJ, Starr JM, Deary IJ, Calibrating ADL-IADL
    scales to improve measurement accuracy and to extend the
    disability construct into the preclinical range: a systematic
    review, BMC Geriatr, 2011;11:42.

  45. Gauthier S, Gélinas I, Gauthier L, Functional disability in
    Alzheimer’s disease, Int Psychogeriatr, 1997;9:163–5.

  46. Nygård L, Instrumental activities of daily living: a
    stepping-stone towards Alzheimer’s disease diagnosis
    in subjects with mild cognitive impairment?,
    Acta Neurol Scand, 2003;107:42–6.

  47. Mason SE, McShane R, Ritchie CW, Diagnostic tests for
    Alzheimer’s disease: rationale, methodology, and
    challenges, Int J Alzheimer Dis, 2010 Aug 8 [Epub ahead of
    print].

  48. Ritchie C, Masters CL, Mason SE, et al., Plasma and CSF
    Abeta for the longitudinal prediction of Alzheimer’s disease
    dementia and other dementias in people with cognitive
    decline but no dementia [Protocol], Cochrane DB Syst Rev,
    2011;1:CD008782.

  49. Filippini G, Casazza G, Bellatorre AG, et al., The role of MRI
    in the early diagnosis of Alzheimer’s disease or other
    dementias in persons with mild cognitive impairment (MCI)
    [Protocol], Cochrane DB Syst Rev, 2012;2:CD009628.

3

Article Information

Disclosure

The authors have no conflicts of interest to declare.

Correspondence

John M Starr, Alzheimer Scotland Dementia Research Centre, 7 George Square, Edinburgh EH8 9JZ, UK. E: jstarr@staffmail.ed.ac.uk

Received

2012-05-27T00:00:00

4

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Close Popup